EFFICACY AND SAFETY OF ROFLUMILAST CREAM 0.15% IN ADULTS AND CHILDREN AGED 6 AND OLDER WITH MILD TO MODERATE ATOPIC DERMATITIS IN TWO PHASE 3 INTEGUMENT TRIALS

被引：0
|
作者：
Simpson, E. [1 ]
Eichenfield, L. F. [2 ,3 ]
Gooderham, M. [4 ,5 ]
Gonzalez, M. [6 ]
Hebert, A. A. [7 ]
Papp, K. A. [8 ]
Prajapati, V [9 ,10 ]
Krupa, D. [11 ]
Burnett, P. [11 ]
Berk, D. R. [11 ]
Higham, R. [11 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Univ Calif San Diego, San Diego, CA 92103 USA
[3] Rady Childrens Hosp, San Diego, CA 92103 USA
[4] Prob Med Res, SKiN Ctr Dermatol, Peterborough, ON, Canada
[5] Queens Univ, Peterborough, ON, Canada
[6] Pediat Skin Res LLC, Miami, FL USA
[7] UT Hlth McGovern Med Sch, Houston, TX USA
[8] Prob Med Res & Alliance Clin Res, Waterloo, ON, Canada
[9] Univ Calgary, Dermatol Res Inst, Skin Hlth & Wellness Ctr, Calgary, AB, Canada
[10] Prob Med Res, Calgary, AB, Canada
[11] Arcutis Biotherapeut Inc, Westlake Village, CA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO136
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of roflumilast cream 0.15% in adults and children aged=6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2)
    Simpson, Eric
    Eichenfield, Lawrence
    Gooderham, Melinda
    Gonzalez, Mercedes E.
    Hebert, Adelaide
    Papp, Kim
    Prajapati, Vimal
    Krupa, David
    Burnett, Patrick
    Berk, David
    Higham, Robert
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [2] Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis
    Simpson, Eric
    Boguniewicz, Mark
    Eichenfield, Lawrence
    Gonzales, Mercedes E.
    Hebert, Adelaide A.
    Prajapati, Vimal H.
    Gooderham, Melinda
    Krupa, David
    Chu, David H.
    Higham, Robert C.
    Berk, David R.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [3] Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials
    Simpson, Eric L.
    Eichenfield, Lawrence F.
    Alonso-Llamazares, Javier
    Draelos, Zoe D.
    Ferris, Laura K.
    Forman, Seth B.
    Gooderham, Melinda
    Gonzalez, Mercedes E.
    Hebert, Adelaide A.
    Kircik, Leon H.
    Lomaga, Mark
    Moore, Angela
    Papp, Kim A.
    Prajapati, Vimal H.
    Hanna, Diane
    Snyder, Scott
    Krupa, David
    Burnett, Patrick
    Almaraz, Erin
    Higham, Robert C.
    Chu, David H.
    Berk, David R.
    JAMA DERMATOLOGY, 2024, 160 (11) : 1161 - 1170
  • [4] Long-term safety and efficacy of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis: a 52-week, phase 3, open-label extension trial
    Simpson, Eric L.
    Eichenfield, Lawrence F.
    Papp, Kim A.
    Forman, Seth
    Hebert, Adelaide A.
    Gonzalez, Mercedes E.
    Gooderham, Melinda
    Hong, H. Chih-ho
    Prajapati, Vimal H.
    Guttman, Emma
    Silverberg, Jonathan
    Seal, Melissa
    Krupa, David
    Burnett, Patrick
    Synder, Scott
    Chu, David H.
    Higham, Robert C.
    Berk, David R.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 20 - 20
  • [5] ONCE-DAILY ROFLUMILAST CREAM 0.15% FOR ATOPIC DERMATITIS: POOLED RESULTS: FROM INTEGUMENT-1/2 PHASE 3 TRIALS
    Eichenfield, L.
    Boguniewicz, M.
    Simpson, E.
    Blauvelt, A.
    Gooderham, M.
    Lain, E.
    Chu, D.
    Higham, R.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S91 - S91
  • [6] Once-daily roflumilast cream 0.15% for atopic dermatitis: pooled results from INTEGUMENT-1/2 phase 3 trials
    Eichenfield, Lawrence F.
    Boguniewicz, Mark
    Simpson, Eric L.
    Blauvelt, Andrew
    Gooderham, Melinda
    Lain, Edward
    Chu, David H.
    Higham, Robert C.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II10 - II11
  • [7] Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial
    Simpson, Eric L.
    Eichenfield, Lawrence F.
    Papp, Kim A.
    Forman, Seth B.
    Hebert, Adelaide A.
    Gonzalez, Mercedes E.
    Gooderham, Melinda J.
    Hong, H. Chih-ho
    Prajapati, Vimal H.
    Guttman-Yassky, Emma
    Silverberg, Jonathan I.
    Seal, Melissa S.
    Krupa, David
    Almaraz, Erin
    Hanna, Diane
    Burnett, Patrick
    Snyder, Scott
    Chu, David H.
    Higham, Robert C.
    Berk, David R.
    DERMATITIS, 2025,
  • [8] The safety and efficacy of roflumilast cream 0.15% and 0.05% in atopic dermatitis: phase II proof-of-concept study
    Gooderham, M. J.
    Kircik, L. H.
    Zirwas, M.
    Lee, M.
    Kempers, S. E.
    Draelos, Z. D.
    Ferris, L. K.
    Jones, T. M.
    Proulx, E. Saint-Cyr
    Bissonnette, R.
    Bhatia, N.
    Guenthner, S. T.
    Koppel, R. A.
    Welgus, H.
    Merritt, C.
    Elias, M.
    Navale, L.
    Higham, R. C.
    Droege, M.
    Berk, D. R.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E69 - E69
  • [9] Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial
    Eichenfield, Lawrence F.
    Serrao, Rocco
    Prajapati, Vimal H.
    Browning, John C.
    Swanson, Lisa
    Funk, Tracy
    Gonzalez, Mercedes E.
    Hebert, Adelaide A.
    Lee, Mark
    Boguniewicz, Mark
    Simpson, Eric L.
    Seal, Melissa S.
    Krupa, David
    Hanna, Diane
    Snyder, Scott
    Burnett, Patrick
    Chu, David H.
    Almaraz, Erin
    Higham, Robert C.
    Berk, David R.
    PEDIATRIC DERMATOLOGY, 2025,
  • [10] Efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients 2 to 5 years of age with mild to moderate atopic dermatitis (INTEGUMENT-PED): a phase 3 randomized controlled trial
    Eichenfield, Lawrence
    Browning, John
    Funk, Tracy
    Gonzalez, Mercedes E.
    Hebert, Adelaide A.
    Lee, Mark
    Prajapati, Vimal H.
    Serrao, Rocco
    Swanson, Lisa
    Higham, Robert
    Berk, David
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
12345